Share this post on:

Cinda biology up more than 6% FDA accepts cindilimab combined with pemetrexed
Cinda bio (01801) announced that the U.S. Food and drug administration has officially accepted the new drug application for the first-line treatment of non squamous non-small cell lung cancer, which is an innovative PD-1 inhibitor developed jointly by the company and Eli Lilly. This is the first new drug application of sindilimab in the United States. It is up 6.49% at a price of HK $92.7 with a turnover of HK $576.7 million.